Journey Medical's new rosacea treatment will rival industry giant Galderma's Oracea in the treatment of rosacea.

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care ...

The FDA approved Emrosi (minocycline hydrochloride extended-release capsules) for the treatment of inflammatory lesions of rosacea in adults.

Journey Medical (DERM) announced the FDA has approved Emrosi for the treatment of inflammatory lesions of rosacea in adults. Emrosi ...

Dermatology drugmaker Journey Medical has trekked its Dr. Reddy’s Laboratories-partnered rosacea med across the FDA finish line as Emrosi. | The drug proved superiority in clearing lesions over ...

Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved minocycline hydrochloride ...

Journey Medical (DERM) received FDA approval for its drug Emrosi for the treatment of rosacea and released its preliminary Q3 ...

The U.S. Food and Drug Administration has approved Journey Medical's drug for the treatment of a long-term skin condition ...

Journey Medical (DERM) announced that the FDA has approved Emrosi, formerly referred to as DFD-29, for the treatment of inflammatory lesions of ...

Personalised cancer vaccines offer significant potential to address an unmet medical need in treatment-resistant disease with fewer side effects and less toxicity compared to standard treatment, such ...